



(11) Publication number : **0 439 061 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(43) Date of publication of patent specification :  
27.07.94 Bulletin 94/30

(51) Int. Cl.<sup>5</sup>: **A61K 33/14, A61K 33/10,  
A61K 33/06**

(21) Application number : **91100527.0**

(22) Date of filing : **17.01.91**

(54) **Intravenous solutions for influencing renal function and for maintenance therapy.**

(30) Priority : **19.01.90 US 467166**

(43) Date of publication of application :  
31.07.91 Bulletin 91/31

(45) Publication of the grant of the patent :  
27.07.94 Bulletin 94/30

(64) Designated Contracting States :  
**DE FR GB IT SE**

(56) References cited :  
**EP-A- 437 274  
EP-A- 0 076 658  
EP-A- 0 177 614  
WO-A-87/03808  
WO-A-87/03809  
DE-A- 2 358 759**

(73) Proprietor : **Kopp, Klaus F. Dr.  
Asslkofener Strasse 4  
D-85560 Ebersberg (DE)**

(72) Inventor : **Kopp, Klaus F. Dr.  
Asslkofener Strasse 4  
D-85560 Ebersberg (DE)**

(74) Representative : **Müller-Boré & Partner  
Patentanwälte  
Postfach 26 02 47  
D-80059 München (DE)**

**EP 0 439 061 B1**

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

pH 7,43, PCO<sub>2</sub> 42 mmHg, HCO<sub>3</sub><sup>-</sup> 28 mmol/l, BA + 3,9.

#### Summary:

5 High daily urine volumes. Progression without complications. Observation period 2 days. Metabolites concentration, electrolytes and blood gases essentially normal.

Diagnosis: Stenosis of Urethra, Prostata-Carcinoma, Diab. mellitus

Operation: Pelvine Lymphadenectomy

10 Progression: Diuresis: 1st day: 2880 ml  
2nd day: 2200 ml  
3rd day: 4030 ml

#### Infusion program:

15 1st day: 2000 ml Bicarbonate-electrolyte solution, + 20 mg Lasix + 40 mval KCl  
1000 ml Glucose 5 %  
2nd day: 2000 ml Bicarbonate-electrolyte solution, 40 mval KCl, 20 mg Lasix  
1000 ml Glucose 5 %  
3rd day: 2000 ml Bicarbonate-electrolyte solution, + 40 mval KCl, 20 mg Lasix  
20 4th day: 1000 ml Bicarbonate-electrolyte solution, + 40 mval KCl, 20 mg Lasix

#### Balance:

1st day: - 470 ml  
25 2nd day: + 1490 ml  
3rd day: - 530 ml

#### Serum values:

30 1st day: Urea-N. 21 mg/dl (norm 7-18), Uric acid 8,9 mg/dl (-7)  
other values normal  
2nd day: mild higher value of Urea N. and Uric acid  
Protein 4,9 g/dl (6-8), Ca 7,8 mg/dl (8,7-10,5)  
pH 7,41, PCO<sub>2</sub> 49 mmHg, HCO<sub>3</sub><sup>-</sup> 31 mmol/l, BA + 5,4  
35 3rd day: Chloride 96 mmol/l (97-108), Ca. 7,8 mg/dl, Protein 4,9 g/dl  
other values normal  
pH 7,49, PCO<sub>2</sub> 48 mmHg, HCO<sub>3</sub><sup>-</sup> 37, BA + 12,5  
4th day: Uric acid. 8,9 mg/dl, Potassium 3,4 mmol/l, Ca 8 mg/dl  
40 Phosphor 2,3 mg/dl (2,5-4,5), Protein 4,9 g/dl  
other values normal

#### Summary:

45 High daily urine volumes. Stabilized metabolites, electrolytes-values, Protein mildly lower. Transferred to General clinic on 4th postoperative day = end of observation. Uncomplicated progression.

The components of the solutions may be provided in combined or separated form. Of course, the solutions of the invention may comprise additional substances, such as pharmaceuticals, trace elements, soluble and stable Ca and/or Mg compounds. For example Ca and/or Mg compounds or components may be provided in a container, such as a flexible bag, separate from the bicarbonate component.

#### Claims

55 1. Use of an aqueous solution comprising at least the following electrolytes at the concentration indicated below:

mval/l.

$\text{Na}^+$	130 to 150
$\text{K}^+$	0 to 6
$\text{Cl}^-$	80 to 125
$\text{HCO}_3^-$	25 to 70

in the preparation of an intravenous medication solution in the treatment of patients suffering from renal dysfunction or renal failure to increase urine volume and stabilize acid-base balance.

2. The use of an aqueous solution according to claim 1, in which the electrolytes are at the concentrations indicated below:

mval/l.

$\text{Na}^+$	135 to 146
$\text{K}^+$	2 to 5
$\text{Cl}^-$	90 to 110
$\text{HCO}_3^-$	40 to 60

3. The use of an aqueous solution according to claim 2, in which the electrolytes are at the concentrations indicated below:

mval/l.

$\text{Na}^+$	146
$\text{K}^+$	4
$\text{Cl}^-$	90
$\text{HCO}_3^-$	60

4. The use of an aqueous solution according to any one of claims 1 to 3, wherein the treatment is followed by a maintenance therapy using an aqueous solution comprising  $\text{HCO}_3^-$  in the range of 25 to < 40 mval/l.
5. The use of an aqueous solution according to any one of claims 1 to 4, in which the aqueous solutions are provided in conjunction with a solution of a Ca and/or Mg compound.
6. The use of an aqueous solution according to claim 5, in which the solution of the Ca and/or Mg compound is provided in a container, such as a flexible bag, which is separate from the  $\text{HCO}_3^-$  electrolyte.
7. The use of an aqueous solution according to any one of the claims 1 to 6, in which the therapy involves administration of diuretics to increase diuresis.
8. The use of an aqueous solution according to claim 7, in which the therapy involves administration of loop diuretics to increase diuresis.